EP1937242A4 - Verfahren und zusammensetzungen zur behandlung neuropsychiatrischer erkrankungen und suchtkrankheiten - Google Patents

Verfahren und zusammensetzungen zur behandlung neuropsychiatrischer erkrankungen und suchtkrankheiten

Info

Publication number
EP1937242A4
EP1937242A4 EP06826134A EP06826134A EP1937242A4 EP 1937242 A4 EP1937242 A4 EP 1937242A4 EP 06826134 A EP06826134 A EP 06826134A EP 06826134 A EP06826134 A EP 06826134A EP 1937242 A4 EP1937242 A4 EP 1937242A4
Authority
EP
European Patent Office
Prior art keywords
neuropsychiatric
compositions
treatment
methods
addictive disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06826134A
Other languages
English (en)
French (fr)
Other versions
EP1937242A2 (de
Inventor
Daryl W Hochman
John J Partridge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuroTherapeutics Pharma Inc
Original Assignee
NeuroTherapeutics Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/251,724 external-priority patent/US8008283B2/en
Priority claimed from US11/549,274 external-priority patent/US20070149526A1/en
Application filed by NeuroTherapeutics Pharma Inc filed Critical NeuroTherapeutics Pharma Inc
Publication of EP1937242A2 publication Critical patent/EP1937242A2/de
Publication of EP1937242A4 publication Critical patent/EP1937242A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP06826134A 2005-10-17 2006-10-17 Verfahren und zusammensetzungen zur behandlung neuropsychiatrischer erkrankungen und suchtkrankheiten Withdrawn EP1937242A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72731805P 2005-10-17 2005-10-17
US72756405P 2005-10-17 2005-10-17
US11/251,724 US8008283B2 (en) 1998-12-23 2005-10-17 Methods and compositions for the treatment of neuropsychiatric disorders
US11/549,274 US20070149526A1 (en) 2005-10-17 2006-10-13 Diuretic and diuretic-like compound analogs
PCT/US2006/040598 WO2007047698A2 (en) 2005-10-17 2006-10-17 Methods and compositions for the treatment of neuropsychiatric and addictive disorders

Publications (2)

Publication Number Publication Date
EP1937242A2 EP1937242A2 (de) 2008-07-02
EP1937242A4 true EP1937242A4 (de) 2011-06-15

Family

ID=37963225

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06826134A Withdrawn EP1937242A4 (de) 2005-10-17 2006-10-17 Verfahren und zusammensetzungen zur behandlung neuropsychiatrischer erkrankungen und suchtkrankheiten

Country Status (2)

Country Link
EP (1) EP1937242A4 (de)
WO (1) WO2007047698A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017042314A1 (en) * 2015-09-11 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of post-traumatic epilepsies
US11666547B2 (en) * 2019-06-28 2023-06-06 Northwestern University Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082252A1 (en) * 1998-12-23 2002-06-27 Cytoscan Sciences L.L.C. Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms
WO2007047447A2 (en) * 2005-10-17 2007-04-26 Neurotherapeutics Pharma, Inc. Diuretic-like compound analogs useful for regulation of central nervous system disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128327A (en) * 1991-03-25 1992-07-07 Merck & Co., Inc. Angiotensin II antagonists incorporating a nitrogen containing six membered ring heterocycle
US5162325A (en) * 1991-05-07 1992-11-10 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted benzyl element

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082252A1 (en) * 1998-12-23 2002-06-27 Cytoscan Sciences L.L.C. Methods and compositions for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms
WO2007047447A2 (en) * 2005-10-17 2007-04-26 Neurotherapeutics Pharma, Inc. Diuretic-like compound analogs useful for regulation of central nervous system disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. A. COLLINS ET AL.: "Brain damage due to episodic alcohol exposure in vivo and in vitro: furosemide neuroprotection implicates edema-based mechanism", THE FASEB JOURNAL, vol. 12, 1998, pages 221 - 230, XP002634773 *

Also Published As

Publication number Publication date
EP1937242A2 (de) 2008-07-02
WO2007047698A3 (en) 2007-07-05
WO2007047698A2 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
ZA200607433B (en) Methods and compositions for the treatment of gastroin-testinal disorders
EP1853295A4 (de) Verfahren und zusammensetzungen zur behandlung gastrointestinaler erkrankungen
EP1940441A4 (de) Verfahren und zusammensetzungen zur behandlung von gastrointestinalen störungen
EP1874286A4 (de) Verfahren und zusammensetzungen zur behandlung von angstzuständen
IL177772A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
EP1893216A4 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL190913B (en) Preparations for the treatment of sweating disorders
IL180187A0 (en) Compositions and methods for treating inflammatory disorders
IL191283A (en) Compositions for treating eye irregularities
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
PL1644021T3 (pl) Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych
ZA200704964B (en) Methods and compositions using immunomodulatory compounds for the treatment of immunodeficiency disorders
IL191537A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
EP1996218A4 (de) Verfahren und zusammensetzungen zur behandlung gastrointestinaler erkrankungen
ZA200610661B (en) Compositions and methods for treating neurological disorders
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
ZA200804951B (en) Compositions and methods for treating CNS disorders
IL162288A0 (en) Compositions and methods for treating neurodegenerative disorders
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
ZA200707955B (en) Methods and pharmaceutical compositions for the treatment of neurological damage
EP1912630A4 (de) Zusammensetzungen und verfahren zur verringerung von postoperativen schmerzen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080331

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031195000

Ipc: C07D0307520000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/08 20060101ALI20110502BHEP

Ipc: A61K 31/41 20060101ALI20110502BHEP

Ipc: A61K 31/381 20060101ALI20110502BHEP

Ipc: A61K 31/341 20060101ALI20110502BHEP

Ipc: C07D 207/06 20060101ALI20110502BHEP

Ipc: C07C 311/00 20060101ALI20110502BHEP

Ipc: C07D 213/34 20060101ALI20110502BHEP

Ipc: C07D 257/04 20060101ALI20110502BHEP

Ipc: C07D 333/10 20060101ALI20110502BHEP

Ipc: C07D 307/52 20060101AFI20110502BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20110513

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20111213